ClearPoint Neuro, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joseph Michael Burnett
- Full Time Employees
- 115
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 120 S. Sierra Avenue Solana Beach CA United States of America 92075
- IPO Date
- May 22, 2012
- CIK
- 0001285550
- Website
- clearpointneuro.com
- Similar Companies
- Business
- ClearPoint Neuro, Inc. (Nasdaq:CLPT) is a global device, cell, and gene therapy-enabling company offering precise navigation and delivery solutions to the brain and spine. Founded in 1998 and headquartered in Solana Beach, California, the company provides the ClearPoint Neuro Navigation System, an FDA-cleared and CE-marked integrated platform for minimally invasive procedures including deep brain stimulation electrode insertion, biopsy needle placement, laser catheter ablation via the ClearPoint PRISM Laser Therapy System, and pharmaceutical infusions; SmartFrame OR for stereotactic neurosurgery; ClearPoint Maestro Brain Model for procedural planning; ClearPoint Array Platform; associated disposables and software; and preclinical development services through ClearPoint Advanced Laboratories (CAL), including GLP studies for central nervous system (CNS) drug delivery. It serves neurosurgeons, biopharma partners conducting over 60 gene and cell therapy programs, research centers, and patients targeting complex neurological disorders such as tumors, epilepsy, and Parkinson's disease; operations span healthcare and research facilities in North America, Europe, Asia, South America, with regulatory approvals in 34 countries including recent expansions in Canada, Hong Kong, and Taiwan. Recent developments include FDA 510(k) clearance in 2025 for ClearPoint PRISM compatibility with 1.5T MRI scanners, operational launch of the CAL facility in Torrey Pines, California, prototype demonstration of a Robotic Neuro-Navigation System integrating KUKA LBR Med arm for MRI, CT, and robotic workflows, a note financing arrangement with Oberland Capital providing up to $110 million including $30 million initially funded in 2025, and completion of the acquisition of IRRAS Holdings, Inc. on November 20, 2025 for $5 million cash and 1.325 million shares, adding the IRRAflow active fluid-exchange system for intracranial hemorrhage management, over 50 customers, and expanded commercial scale in neurocritical care.
ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
ClearPoint Neuro, Inc. (CLPT) Q1 2026 Earnings Call Transcript
Compared to Estimates, ClearPoint Neuro (CLPT) Q1 Earnings: A Look at Key Metrics
ClearPoint Neuro, Inc. (CLPT) Reports Q1 Loss, Lags Revenue Estimates
ClearPoint Neuro Q1 Earnings Call Highlights
ClearPoint Neuro Reports First Quarter 2026 Results
ClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprint
Here Are Friday’s Top Wall Street Analyst Research Calls: Applied Materials, Devon Energy, Epam Systems, HubSpot, Nike, Shake Shack, Tapestry, Qualcomm, and More
ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026
ClearPoint Neuro: Temporary Headwinds Don't Change The Long-Term Outlook
ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint
ClearPoint Neuro, Inc. (CLPT) Q4 2025 Earnings Call Transcript
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates
ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results
ClearPoint Neuro (CLPT) Moves 8.1% Higher: Will This Strength Last?
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2025 Results March 17, 2026
CLPT Gets EU MDR Certification for ClearPoint Navigation Software
ClearPoint Neuro: From Validation To Scale
ClearPoint Neuro Gets EU Green Light For Updated Brain Surgery Software